AIM ImmunoTech (AIM) Profit After Tax (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Profit After Tax data on file, last reported at -$3.0 million in Q1 2026.

• Quarterly Profit After Tax rose 18.41% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.3 million (up 12.7% YoY) and the FY2025 annual result came in at -$14.0 million, up 19.41% from the prior year.
• Profit After Tax grew to -$3.0 million in Q1 2026, from -$4.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.8 million in Q2 2024 to a low of -$12.6 million in Q4 2023.
• A 5-year average of -$4.9 million and a median of -$4.2 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 186.53% — and 2024, when it surged 62.6%.
• Tracing AIM's Profit After Tax over 5 years: stood at -$4.4 million in 2022, then plunged by 186.53% to -$12.6 million in 2023, then surged by 52.55% to -$6.0 million in 2024, then soared by 30.03% to -$4.2 million in 2025, then increased by 27.59% to -$3.0 million in 2026.
• The last three Profit After Tax figures came in at -$3.0 million (Q1 2026), -$4.2 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.